Neuropace Stock Options
| NPCE Stock | USD 15.05 0.55 3.79% |
Neuropace's latest option contracts expiring on May 15th 2026 are carrying combined implied volatility of 1.4. The Neuropace option chain provides detailed quote and price information for the current Neuropace option contracts. It shows all of Neuropace's listed puts, calls, expiration dates, strike prices, and other pricing information.
Neuropace Maximum Pain Price Across 2026-05-15 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Neuropace close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, Neuropace's option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Neuropace
Analyzing Neuropace's in-the-money options over time can help investors to take a profitable long position in Neuropace regardless of its overall volatility. This is especially true when Neuropace's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Neuropace's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Neuropace's stock while costing only a fraction of its price.
Neuropace's stock options are financial instruments that give investors the right to buy or sell shares of Neuropace common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Neuropace stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Neuropace's stock price goes up or down, the stock options follow.
The current year's Total Stockholder Equity is expected to grow to about 9.7 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 21.7 M. Neuropace In The Money Call Balance
When Neuropace's strike price is surpassing the current stock price, the option contract against Neuropace stock is said to be in the money. When it comes to buying Neuropace's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Neuropace are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Neuropace Current Options Market Mood
Neuropace's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Neuropace Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Neuropace's options investors are not very successful. Neuropace's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Neuropace contract
Base on the Rule 16, the options market is currently suggesting that Neuropace will have an average daily up or down price movement of about 0.0875% per day over the life of the 2026-05-15 option contract. With Neuropace trading at USD 15.05, that is roughly USD 0.0132. If you think that the market is fully incorporating Neuropace's daily price movement you should consider buying Neuropace options at the current volatility level of 1.4%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Neuropace | Build AI portfolio with Neuropace Stock |
Purchasing Neuropace options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Neuropace calls. Remember, the seller must deliver Neuropace stock to the call owner when a call is exercised.
Neuropace Option Chain
When Neuropace's strike price is surpassing the current stock price, the option contract against Neuropace stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Neuropace's option chain is a display of a range of information that helps investors for ways to trade options on Neuropace. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Neuropace. It also shows strike prices and maturity days for a Neuropace against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | NPCE260515C00030000 | 0 | 30.0 | 0.0 - 4.0 | 4.0 | |
Call | NPCE260515C00025000 | 0 | 25.0 | 0.0 - 4.8 | 4.8 | |
Call | NPCE260515C00022500 | 0 | 22.5 | 0.05 - 4.8 | 0.05 | |
Call | NPCE260515C00020000 | 2 | 20.0 | 0.05 - 4.8 | 1.3 | Out |
Call | NPCE260515C00017500 | 1 | 17.5 | 0.05 - 4.9 | 0.95 | Out |
Call | NPCE260515C00015000 | 11 | 15.0 | 1.0 - 4.9 | 3.3 | Out |
Call | NPCE260515C00012500 | 2 | 12.5 | 2.3 - 6.5 | 4.6 | In |
Call | NPCE260515C00010000 | 2 | 10.0 | 3.8 - 8.5 | 7.0 | In |
Call | NPCE260515C00007500 | 2 | 7.5 | 5.5 - 10.1 | 7.5 | In |
Call | NPCE260515C00005000 | 0 | 5.0 | 8.2 - 12.9 | 11.18 | In |
Put | NPCE260515P00030000 | 0 | 30.0 | 12.5 - 16.8 | 12.5 | In |
Put | NPCE260515P00025000 | 0 | 25.0 | 7.9 - 12.5 | 7.9 | In |
Put | NPCE260515P00022500 | 0 | 22.5 | 5.6 - 10.0 | 5.6 | In |
Put | NPCE260515P00020000 | 0 | 20.0 | 3.2 - 7.9 | 3.2 | In |
Put | NPCE260515P00017500 | 0 | 17.5 | 1.3 - 5.8 | 1.3 | In |
Put | NPCE260515P00015000 | 0 | 15.0 | 0.1 - 4.9 | 0.1 | |
Put | NPCE260515P00012500 | 0 | 12.5 | 0.05 - 4.9 | 2.5 | |
Put | NPCE260515P00010000 | 0 | 10.0 | 0.0 - 4.5 | 4.5 | |
Put | NPCE260515P00007500 | 0 | 7.5 | 0.0 - 4.0 | 4.0 | |
Put | NPCE260515P00005000 | 0 | 5.0 | 0.0 - 1.55 | 1.55 |
Neuropace Total Stockholder Equity
Total Stockholder Equity |
|
Neuropace Corporate Management
| Irina Ridley | Chief Secretary | Profile | |
| Chi Nguyen | VP Marketing | Profile | |
| Kelley Nicholas | Vice Sales | Profile | |
| Michael Favet | CEO Pres | Profile | |
| Katie Keller | Vice Marketing | Profile | |
| Patrick Williams | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.